Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants

Abstract

Palifermin, a recombinant human keratinocyte growth factor, is commonly given to prevent mucositis following autologous transplantation. In the allogeneic hematopoietic stem cell transplant (allo-HSCT) setting, safety and efficacy data are limited. We conducted a retrospective study in 251 patients undergoing allo-HSCT, 154 of whom received peritransplant palifermin. In all patients, palifermin significantly decreased the mean number of days of total parenteral nutrition (TPN, 13 vs 16 days, P=0.006) and patient-controlled analgesia (PCA, 6 vs 10 days, P=0.023), as well as the length of initial hospital stay (LOS, 32 vs 37 days, P=0.014). However, the effect of palifermin was only significant in patients who received a TBI- but not BU-based chemotherapy conditioning regimen. In TBI recipients, palifermin decreased the mean number of days of TPN (13 vs 17 days, P<0.001) and PCA (7 vs 12 days, P=0.033), and the length of stay (32 vs 38 days, P=0.001). Palifermin did not affect GVHD, graft failure or relapse. Therefore, in the largest analysis with this patient population to date, we demonstrate that palifermin is safe in allo-HSCT patients, decreases TPN and PCA use and decreases LOS following TBI-based but not chemotherapy-based allo-HSCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383–388.

    Article  CAS  PubMed  Google Scholar 

  2. Woo SB, Sonis ST, Monopoli MM, Sonis AL . A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612–1617.

    Article  CAS  PubMed  Google Scholar 

  3. McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB . Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 1993; 20: 1493–1502.

    CAS  PubMed  Google Scholar 

  4. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201–2205.

    Article  CAS  PubMed  Google Scholar 

  5. Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA . Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA 1989; 86: 802–806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Werner S, Peters KG, Longaker MT, Fuller-Pace F, Banda MJ, Williams LT . Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc Natl Acad Sci USA 1992; 89: 6896–6900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Dorr W, Kummermehr J . Increased radiation tolerance of mouse tongue epithelium after local conditioning. Int J Radiat Biol 1992; 61: 369–379.

    Article  CAS  PubMed  Google Scholar 

  8. Dorr W, Noack R, Spekl K, Farrell CL . Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int J Radiat Biol 2001; 77: 341–347.

    Article  CAS  PubMed  Google Scholar 

  9. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58: 933–939.

    CAS  PubMed  Google Scholar 

  10. Farrell CL, Rex KL, Kaufman SA, Dipalma CR, Chen JN, Scully S et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 1999; 75: 609–620.

    Article  CAS  PubMed  Google Scholar 

  11. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21: 1452–1458.

    Article  CAS  PubMed  Google Scholar 

  12. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.

    Article  CAS  PubMed  Google Scholar 

  13. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216–3222.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275–279.

    Article  CAS  PubMed  Google Scholar 

  15. Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983–988.

    Article  CAS  PubMed  Google Scholar 

  16. Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 2011; 17: 1343–1351.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ho VT . Ex vivo T cell depletion of allogeneic PBSC as acute and chronic GVHD prophylaxis after myeloablative HCT: time to reconsider? Biol Blood Marrow Transplant 2011; 17: 1112–1113.

    Article  PubMed  Google Scholar 

  18. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008; 14: 458–468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083–1090.

    CAS  PubMed  Google Scholar 

  20. Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 2007; 110: 4552–4559.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Shank B, Chu FC, Dinsmore R, Kapoor N, Kirkpatrick D, Teitelbaum H et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 1983; 9: 1607–1611.

    Article  CAS  PubMed  Google Scholar 

  22. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. British journal of haematology 1997; 97: 855–864.

    Article  CAS  PubMed  Google Scholar 

  23. Sullivan KM . Chronic graft-versus-host disease. Cancer Treat Res 1990; 50: 79–98.

    Article  CAS  PubMed  Google Scholar 

  24. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94: 825–831.

    CAS  PubMed  Google Scholar 

  25. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR . Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960–3967.

    CAS  PubMed  Google Scholar 

  26. Le QT, Kim HE, Schneider CJ, Murakozy G, Skladowski K, Reinisch S et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 2011; 29: 2808–2814.

    Article  CAS  PubMed  Google Scholar 

  27. Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol 2011; 29: 2815–2820.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the expert care provided to these patients by the fellows, housestaff and nurses of Memorial Sloan-Kettering Cancer Center. This study was supported in part by NIH P01 CA23766; research funding was obtained from Swedish Orphan Biovitrium (JDG and M-AP), the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center funded by Mr William H Goodwin and Mrs Alice Goodwin (M-AP), New York Community Trust (M-AP), and Cycle for Survival (M-AP).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J D Goldberg.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldberg, J., Zheng, J., Castro-Malaspina, H. et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 48, 99–104 (2013). https://doi.org/10.1038/bmt.2012.115

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.115

Keywords

This article is cited by

Search

Quick links